Cargando…

Role of MDM2 Overexpression in Doxorubicin Resistance of Breast Carcinoma

Several oncoproteins or tumor suppressor gene products have been indicated to be of value as predictors of the de novo resistance to cytotoxic agents. In this study, we have investigated the role of MDM2 (murine double minutes) overexpression in doxorubicin resistance of breast cancer. Immunocytoche...

Descripción completa

Detalles Bibliográficos
Autores principales:	Suzuki, Akio, Toi, Masakazu, Yamamoto, Yutaka, Saji, Shigehira, Muta, Mariko, Tominaga, Takeshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 1998
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5921757/ https://www.ncbi.nlm.nih.gov/pubmed/9548451 http://dx.doi.org/10.1111/j.1349-7006.1998.tb00552.x

Ejemplares similares

Overexpression of MDM2 in MCF‐7 Promotes Both Growth Advantage and p53 Accumulation in Response to Estradiol
por: Saji, Shigehira, et al.
Publicado: (1999)

Impact of body mass index on breast cancer in accordance with the life-stage of women
por: Suzuki, Reiko, et al.
Publicado: (2012)

Long isoform of VEGF stimulates cell migration of breast cancer by filopodia formation via NRP1/ARHGAP17/Cdc42 regulatory network
por: Kiso, Marina, et al.
Publicado: (2018)

Differential Involvement of Autophagy and Apoptosis in Response to Chemoendocrine and Endocrine Therapy in Breast Cancer: JBCRG-07TR
por: Ueno, Takayuki, et al.
Publicado: (2019)

Changes in Recurrence Score by neoadjuvant endocrine therapy of breast cancer and their prognostic implication
por: Ueno, Takayuki, et al.
Publicado: (2019)

Circulating cell-free DNA-based epigenetic assay can detect early breast cancer
por: Uehiro, Natsue, et al.
Publicado: (2016)

Significance of Membrane Type 1 Matrix Metalloproteinase Expression in Breast Cancer
por: Ishigaki, Shinsuke, et al.
Publicado: (1999)

Evolving Approaches to Metastatic Breast Cancer Patients Pre-treated with Anthracycline and Taxane
por: Saji, Shigehira
Publicado: (2013)

Erratum to: Evolving Approaches to Metastatic Breast Cancer Patients Pre-treated with Anthracycline and Taxane
por: Saji, Shigehira
Publicado: (2013)

Association of Vascular Endothelial Growth Factor Expression with Tumor Angiogenesis and with Early Relapse in Primary Breast Cancer
por: Toi, Masakazu, et al.
Publicado: (1994)

A phase I/II pharmacokinetics/pharmacodynamics study of irinotecan combined with S−1 for recurrent/metastatic breast cancer in patients with selected UGT1A1 genotypes (the JBCRG‐M01 study)
por: Ishiguro, Hiroshi, et al.
Publicado: (2017)

Clinical significance of the expression of autophagy-associated marker, beclin 1, in breast cancer patients who received neoadjuvant endocrine therapy
por: Ueno, Takayuki, et al.
Publicado: (2016)

Expression of Macrophage Migration Inhibitory Factor in Human Breast Cancer: Association with Nodal Spread
por: Bando, Hiroko, et al.
Publicado: (2002)

Trogocytosis-mediated expression of HER2 on immune cells may be associated with a pathological complete response to trastuzumab-based primary systemic therapy in HER2-overexpressing breast cancer patients
por: Suzuki, Eiji, et al.
Publicado: (2015)

Tumorigenesis promotes Mdm4-S overexpression
por: Pant, Vinod, et al.
Publicado: (2017)

Benzimidazoles Downregulate Mdm2 and MdmX and Activate p53 in MdmX Overexpressing Tumor Cells
por: Mrkvová, Zuzana, et al.
Publicado: (2019)

Modulation of thymidine phosphorylase by neoadjuvant chemotherapy in primary breast cancer
por: Toi, M, et al.
Publicado: (2004)

The role of MDM2 amplification and overexpression in therapeutic resistance of malignant tumors
por: Hou, Helei, et al.
Publicado: (2019)

Neoadjuvant endocrine therapy with exemestane followed by response‐guided combination therapy with low‐dose cyclophosphamide in postmenopausal patients with estrogen receptor‐positive breast cancer: A multicenter, open‐label, phase II study
por: Sato, Nobuaki, et al.
Publicado: (2018)

Neoadjuvant exemestane or exemestane plus docetaxel and cyclophosphamide tailored by clinicopathological response to 12 weeks' exemestane exposure in patients with estrogen receptor‐positive breast cancer: A multicenter, open‐label, phase II study
por: Sato, Nobuaki, et al.
Publicado: (2019)

Impact of clinical response to neoadjuvant endocrine therapy on patient outcomes: a follow-up study of JFMC34-0601 multicentre prospective neoadjuvant endocrine trial
por: Ueno, Takayuki, et al.
Publicado: (2018)

MDM2 overexpression is rare in ovarian carcinoma irrespective of TP53 mutation status.
por: Foulkes, W. D., et al.
Publicado: (1995)

Estradiol Stabilizes p53 Protein in Breast Cancer Cell Line, MCF–7
por: Okumura, Naoki, et al.
Publicado: (2002)

Expression of Multidrug Resistance‐related Transporters in Human Breast Carcinoma
por: Kanzaki, Atsuko, et al.
Publicado: (2001)

Estradiol promotes rapid degradation of HER3 in ER-positive breast cancer cell line MCF-7
por: Suga, Junko, et al.
Publicado: (2018)

Pertuzumab retreatment for HER2‐positive advanced breast cancer: A randomized, open‐label phase III study (PRECIOUS)
por: Yamamoto, Yutaka, et al.
Publicado: (2022)

Differential survival following trastuzumab treatment based on quantitative HER2 expression and HER2 homodimers in a clinic-based cohort of patients with metastatic breast cancer
por: Toi, Masakazu, et al.
Publicado: (2010)

Estrogen receptor alpha (ERα/ESR1) mediates the p53-independent overexpression of MDM4/MDMX and MDM2 in human breast cancer
por: Swetzig, Wendy M., et al.
Publicado: (2016)

The role of MDM2 and MDM4 in breast cancer development and prevention
por: Haupt, Sue, et al.
Publicado: (2017)

Antagonizing MDM2 Overexpression Induced by MDM4 Inhibitor CEP-1347 Effectively Reactivates Wild-Type p53 in Malignant Brain Tumor Cells
por: Mitobe, Yuta, et al.
Publicado: (2023)

Randomized controlled trial of toremifene 120 mg compared with exemestane 25 mg after prior treatment with a non-steroidal aromatase inhibitor in postmenopausal women with hormone receptor-positive metastatic breast cancer
por: Yamamoto, Yutaka, et al.
Publicado: (2013)

Fulvestrant with or without anti‐HER2 therapy in patients in a postmenopausal hormonal state and with ER‐positive HER2‐positive advanced or metastatic breast cancer: A subgroup analysis of data from the Safari study (JBCRG‐C06)
por: Masuyama, Misato, et al.
Publicado: (2023)

Olmutinib Reverses Doxorubicin Resistance in ETS1-Overexpressing Leukemia Cells
por: Zhong, Jiansheng, et al.
Publicado: (2020)

A risk-based subgroup analysis of the effect of adjuvant S-1 in estrogen receptor-positive, HER2-negative early breast cancer
por: Takada, Masahiro, et al.
Publicado: (2023)

Associations of MDM2 and MDM4 Polymorphisms with Early-Stage Breast Cancer
por: Bartnykaitė, Agnė, et al.
Publicado: (2021)

Paradigm Shift toward Reducing Overtreatment of Ductal Carcinoma In Situ of Breast
por: Sagara, Yasuaki, et al.
Publicado: (2017)

Altered expression of major immune regulatory molecules in peripheral blood immune cells associated with breast cancer
por: Kawaguchi, Kosuke, et al.
Publicado: (2016)

Factors associated with prolonged overall survival in patients with postmenopausal estrogen receptor-positive advanced breast cancer using real-world data: a follow-up analysis of the JBCRG-C06 Safari study
por: Kawaguchi, Hidetoshi, et al.
Publicado: (2019)

The Japanese Breast Cancer Society Clinical Practice Guidelines for Breast Cancer Screening and Diagnosis, 2018 Edition
por: Uematsu, Takayoshi, et al.
Publicado: (2019)

Impact of the MDM2 splice-variants MDM2-A, MDM2-B and MDM2-C on cytotoxic stress response in breast cancer cells
por: Huun, Johanna, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_tv22kvac34pnc7cvoko5n3fika